Document Detail


Positron emission tomography in cancer of the head and neck.
MedLine Citation:
PMID:  15620766     Owner:  NLM     Status:  MEDLINE    
Abstract/OtherAbstract:
The use of positron emission tomography (PET) has increased in oncology and in the assessment of head and neck tumours, where it is most useful for recurrent disease. It has good sensitivity and specificity for diagnosis and staging but is generally not necessary except in difficult cases. Quantitative measures of uptake on PET at diagnosis and after treatment do seem to have prognostic value independent of other information about the tumour and so PET may influence management. It also has a role in the identification of an unknown primary site and of synchronous primaries and metastases (often missed by other imaging). Fusion imaging with magnetic resonance (MRI) or computed tomography (CT) adds a new dimension with improved value for each technique.
Authors:
Sharon F Hain
Related Documents :
8565886 - Endoscopic mri: preliminary results of a new technique for visualization and staging of...
15827416 - Pet/ct imaging of metastatic deposit in vertebral paget's disease.
9137966 - Imaging and medical staging of lung cancer.
19581636 - Positron emission tomography in staging early lung cancer: a randomized trial.
21897306 - Tc-99m methoxyisobutylisonitrile parathyroid scintigraphy: the value of adding a whole-...
1955286 - Mri in patients with amyotrophic lateral sclerosis: correlation with clinical features.
Publication Detail:
Type:  Journal Article    
Journal Detail:
Title:  The British journal of oral & maxillofacial surgery     Volume:  43     ISSN:  0266-4356     ISO Abbreviation:  Br J Oral Maxillofac Surg     Publication Date:  2005 Feb 
Date Detail:
Created Date:  2004-12-28     Completed Date:  2005-03-01     Revised Date:  -    
Medline Journal Info:
Nlm Unique ID:  8405235     Medline TA:  Br J Oral Maxillofac Surg     Country:  Scotland    
Other Details:
Languages:  eng     Pagination:  1-6     Citation Subset:  D; IM    
Affiliation:
The Institute of Nuclear Medicine, Middlesex Hospital, UCH NHS Trust and Charing Cross Hospital, Hammersmith Hospitals NHS Trust, London W1T 3AA, UK. s.hain@nucmed.ucl.ac.uk
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:
Carcinoma, Squamous Cell / radionuclide imaging*
Fluorodeoxyglucose F18 / diagnostic use
Head and Neck Neoplasms / radionuclide imaging*
Humans
Lymph Nodes / radionuclide imaging
Neoplasm Metastasis / radionuclide imaging
Neoplasm Recurrence, Local / radionuclide imaging
Neoplasms, Second Primary / radionuclide imaging
Positron-Emission Tomography*
Prognosis
Radiopharmaceuticals / diagnostic use
Sensitivity and Specificity
Chemical
Reg. No./Substance:
0/Radiopharmaceuticals; 63503-12-8/Fluorodeoxyglucose F18

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  A comparison of predicted and measured levels of runoff-related pesticide concentrations in small lo...
Next Document:  A randomised controlled clinical trial to compare the incidence of injury to the inferior alveolar n...